Inomagen Therapeutics

Executive Summary

Inomagen Therapeutics is a privately held, pre-clinical biotechnology company based in Cambridge, Massachusetts, developing a first-in-class non-viral gene therapy for atrial fibrillation (AFib), the most common cardiac arrhythmia. Founded in 2018 and exclusively licensed from Northwestern University, the company's platform aims to address the root cause of AFib by delivering a therapeutic gene directly to cardiac tissue via a minimally invasive procedure. Unlike current treatments that manage symptoms or ablate abnormal tissue, Inomagen's single-dose approach seeks to restore normal electrical conduction, potentially offering a durable, curative option. The therapy leverages over a decade of academic research, and if successful, could transform the treatment paradigm for the millions of AFib patients worldwide.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data in large animal model60% success
• Q2 2027IND-enabling toxicology studies initiation50% success
• Q3 2026Series A financing completion40% success